Helus Pharma, a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, is a key event where industry leaders discuss trends and opportunities in healthcare and biotechnology. The fireside chat will be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website.
The significance of this participation lies in the company's recent strategic positioning. Helus Pharma, the commercial operating name of Cybin Inc., aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. The company is developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. With class-leading data, Helus Pharma intends to improve the treatment landscape by introducing NSAs that may provide durable improvements in mental health.
Central to the company's pipeline is HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), which expedites the development and review of drugs intended to treat serious conditions and that have shown substantial improvement over available therapies. This designation underscores the potential of HLP003 to address a critical need in MDD treatment, where many patients do not respond adequately to existing antidepressants.
Additionally, Helus Pharma is advancing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder (GAD). GAD affects millions worldwide, and current treatments often have limitations in efficacy and tolerability. The company also maintains an extensive research portfolio of investigational NSAs, indicating a broad commitment to addressing various mental health conditions.
The company's focus on NSAs is particularly noteworthy given the growing interest in psychedelic-inspired therapies for mental health. However, Helus Pharma distinguishes itself by developing synthetic molecules that are designed to be more targeted and potentially safer than classic psychedelics. The goal is to achieve rapid and sustained antidepressant and anxiolytic effects without the hallucinogenic side effects often associated with these compounds. This approach could revolutionize how depression and anxiety are treated, offering new hope for patients who have not found relief with conventional treatments.
The conference appearance provides an opportunity for investors and stakeholders to gain insights into the company's strategy, clinical progress, and future plans. It also comes at a time when the mental health therapeutics market is expanding, with increasing recognition of the need for innovative treatments. The global burden of depression and anxiety has been rising, exacerbated by the COVID-19 pandemic, making effective treatments more critical than ever.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, positioning it to conduct global clinical trials and access diverse markets. The company's commitment to helping minds heal is reflected in its pipeline and its engagement with the investment community. The fireside chat at the H.C. Wainwright conference is expected to cover topics such as the latest clinical data, regulatory milestones, and the company's vision for the future of mental health care.
Investors and industry observers will be watching closely for any updates on HLP003's Phase 3 trials and the potential timeline for regulatory submissions. The company's progress could have significant implications for the field of psychiatry, offering new alternatives for patients who are treatment-resistant. Moreover, the success of NSAs could encourage further research into serotonergic pathways and neuroplasticity, potentially unlocking new therapeutic targets for various neurological and psychiatric disorders.
In an era where mental health awareness is at an all-time high, Helus Pharma's emphasis on developing novel treatments is timely. The company's participation in this prestigious conference highlights its commitment to transparency and its proactive approach to keeping the investment community informed. As the conference approaches, all eyes will be on the company's presentations and any announcements that may follow.
For more information about Helus Pharma and its pipeline, visit the company's website at Helus Pharma or view the full press release at InvestorWire.
